• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix claims win as court invalidates drug delivery patent from Mati

November 9, 2021 By Sean Whooley

Ocular Therapeutix logoOcular Therapeutix (NSDQ:OCUL) announced today that an appeals court invalidated a drug delivery system patent held by Mati Therapeutics.

The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated the patent related to a drug delivery system containing dexamethasone, affirming the judgment made in June 2020 by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.

According to a news release, the PTAB decision followed an inter partes review that determined Ocular Therapeutix had proven that all 23 claims of U.S. Patent 9,849,082 B2 (the ‘082 patent), owned by Mati are invalid due to “obviousness.” Mati had previously claimed that Ocular Therapeutix’s first commercial drug product, Dextenza, and its hydrogel platform, had infringed the ‘082 patent.

Mati may seek further review for the recent judgment and has additional patents that may relate to Dextenza or future products Ocular may develop in the future. Still, Ocular said it believes Mati’s patents would be non-infringed or subject to one or more claims of invalidity.

Bedford, Massachusetts-based Ocular Therapeutix designed the FDA-approved Dextenza to treat ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. The treatment is a corticosteroid intracanilicular insert placed in the punctum and designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Dextenza resorbs and exits the nasolacrimal system without the need for removal.

“This court decision validates our strategy to rigorously defend and protect our innovative products, including Dextenza,” Ocular Therapeutix CEO Antony Mattesich said in the release. “We have long believed that Mati’s patent was invalid. We are pleased that the Federal Circuit Court of Appeals has agreed by affirming the judgment of the PTAB.”

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Implants, Legal News, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS